LearnGlossaryMarketStocksSuperinvestorsSign in

INMB

INmune Bio, Inc.

Healthcare · $52M market cap

Verdict

We can't put a fair value on INMB right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-31.3% a year✗
Sales growth-7.5% a year✗
Free cash flow growth—?
Return on invested capital-42.0%✗

Follow INMB

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 15, 2026: no open-market purchases and 1 other filing (stock awards, tax withholding and similar). Why purchases matter

Other filings

Clark Ronnie Duane

director · 2026-09-15

Award

$233K

About INmune Bio, Inc.

INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works